Cellectis S.A. (CLLS)

Market Cap	257.82M +173.1%
Revenue (ttm)	79.59M +61.7%
Net Income	-67.59M
EPS	-0.67
Shares Out	72.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,065
Open	3.700
Previous Close	3.500
Day's Range	3.620 - 3.750
52-Week Range	n/a
Beta	2.71
Analysts	Strong Buy
Price Target	8.50 (+134.81%)
Earnings Date	May 11, 2026

About CLLS

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 7, 2007
• Employees: 229
• Stock Exchange: NASDAQ
• Ticker Symbol: CLLS
• Website: https://www.cellectis.com

Financial Performance

In 2025, Cellectis's revenue was $79.59 million, an increase of 61.72% compared to the previous year's $49.22 million. Losses were -$67.59 million, 83.9% more than in 2024.

Analyst Summary

According to 2 analysts, the average rating for CLLS stock is "Strong Buy." The 12-month stock price target is $8.5, which is an increase of 134.81% from the latest price.

Price Target

$8.5

(134.81% upside)

Analyst Consensus: Strong Buy